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Abstract: Several studies explored the effects of paracetamol (acetaminophen) ingestion on endurance
performance, but their findings are conflicting. Therefore, this review aimed to conduct a meta-
analysis examining the effects of paracetamol ingestion on endurance performance. Five databases
were searched to find relevant studies. The PEDro checklist was used to assess the methodological
quality of the included studies. Data reported in the included studies were pooled in a random-effects
meta-analysis. A total of ten studies with good or excellent methodological quality were included in
the meta-analysis (pooled n = 141). All included studies had a randomized, double-blind, crossover
design. In the main meta-analysis, there was no significant difference between the effects of placebo
and paracetamol on endurance performance (Cohen’s d = 0.09; 95% confidence interval (CI): −0.04,
0.22; p = 0.172). However, an ergogenic effect was found when we considered only the studies that
provided paracetamol 45 to 60 min before exercise (Cohen’s d = 0.14; 95% CI: 0.07, 0.21; p < 0.001). In
a subgroup analysis that focused on time-to-exhaustion tests, there was a significant ergogenic effect
of paracetamol ingestion (Cohen’s d = 0.19; 95% CI: 0.06, 0.33; p = 0.006). There was no significant
difference between placebo and paracetamol in a subgroup analysis that focused on time trial tests
(Cohen’s d = 0.05; 95% CI: −0.12, 0.21; p = 0.561). In conclusion, paracetamol ingestion appears to
enhance performance (a) in time-to-exhaustion endurance tests and (b) when consumed 45 to 60 min
before exercise.
Keywords: ergogenic effects; data synthesis; aerobic endurance
1. Introduction
Paracetamol (acetaminophen) is one of the most popular drugs for pain relief and
fever reduction [1,2]. Paracetamol primarily acts by inhibiting prostaglandin synthesis,
which reduces transduction of the sensory nerves, resulting in decreased nociceptive im-
pulse transmission [3]. Besides the general population, paracetamol is also consumed by
athletes [4,5]. For example, a study conducted among 141 young sub-elite athletes reported
that paracetamol was detected in urine samples of 9.5% of all participants [4]. Similar to
these findings, in a cohort of 98 young regional-to-national-level athletes, Garcin et al. [5]
reported that paracetamol was detected during urinary screening for doping substances
in 9.2% of the participants. The most commonly reported reason for consuming paraceta-
mol among athletes is to decrease pain from previous athletic exertion [4–6]. Currently,
paracetamol use is not prohibited by the World Anti-Doping Agency.
While paracetamol is used in sport and exercise to reduce pain from a previous
exercise bout, less is known about its acute ergogenic effects [7–20]. Acute muscle pain
occurs during different forms of endurance exercise (e.g., middle distance running and
cycling) [21]. It has been proposed that exercise-induced pain tolerance is an important
factor in endurance performance [22,23]. One recent study [22] found that exercise-induced
pain tolerance is significantly correlated with cycling performance (r = 0.83). Accordingly,
researchers have devoted their attention to strategies that ameliorate the perceptions of
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pain during exercise to improve endurance performance [23]. Theoretically, lowering pain
during endurance tasks by consuming paracetamol could improve exercise performance.
One study provided a placebo or paracetamol dose of 1500 mg 60 min before a 16.1 km
cycling time trial to a sample of trained male cyclists [10]. This study reported that acute
ingestion of paracetamol reduced the time needed to complete the cycling event by 45 s [10].
However, more recent studies [9,15,16] used similar protocols and exercise tests but did
not observe an ergogenic effect of paracetamol on endurance performance. In one example,
Jessen et al. [9] reported that power output during 6 min of cycling was similar following
the ingestion of placebo (312 ± 41 W) and 1500 mg of paracetamol (313 ± 45 W).
Due to the conflicting reports, it is currently difficult to provide a conclusive recommen-
dation regarding the ergogenic effects of paracetamol on endurance performance. However,
expanding our knowledge on this topic would be practically relevant because some reports
indicate paracetamol consumption among athletes [4,5]. Therefore, we aimed to conduct a
meta-analysis examining the effects of paracetamol ingestion on endurance performance.
2. Materials and Methods
2.1. Search Strategy
In the primary part of the search process, we searched through five databases: Net-
worked Digital Library of Theses and Dissertations, PubMed/MEDLINE, SPORTDiscus,
Scopus, and Web of Science. We used the following search syntax in all databases: (parac-
etamol OR acetaminophen) AND (“time trial” OR “time to exhaustion” OR running OR
“exercise performance” OR “mean power” OR endurance OR “volitional fatigue”). In the
secondary search, we examined the references list of all included studies and conducted
forward citation tracking through Google Scholar. The search for studies was performed on
5 August 2021. The search was performed independently by the two authors of the review.
2.2. Inclusion Criteria
We included studies that satisfied the following criteria: (1) examined the effects of
paracetamol ingestion on endurance performance; (2) used a double-blind, crossover, and
placebo-controlled study design; (3) included humans as study participants.
2.3. Data Extraction
From all included studies, we extracted the following data: (1) lead author name and
year of publication; (2) participants’ characteristics; (3) protocol of paracetamol ingestion
(e.g., dose and the timing of ingestion); (4) endurance test; (5) mean ± standard deviation
from the endurance test following placebo and paracetamol ingestion. One study [16]
presented mean ± standard deviation data in a figure. For this study, we used the Web
Plot Digitizer software (https://apps.automeris.io/wpd/ (accessed on 6 August 2021)) to
extract the necessary data.
2.4. Methodological Quality
We used the PEDro checklist to assess the methodological quality of the included
studies [24]. This checklist utilizes 11 items evaluating various methodological aspects,
including randomization, inclusion criteria, blinding, allocation concealment, attrition, and
data reporting. Every item on the PEDro checklist is scored as “1” (criterion is satisfied) or
“0” (criterion is not satisfied). However, the first item (“eligibility criteria were specified”)
does not contribute to the total score. Therefore, the maximum possible number of points
that can be scored on the PEDro checklist is 10. Based on this score, studies are classified as
excellent, good, fair, and poor methodological quality if they scored 9–10 points, 6–8 points,
4–5 points, and ≤3 points, respectively [25,26].
2.5. Statistical Analysis
The meta-analysis was performed using standardized mean differences (Cohen’s d).
Cohen’s d effect sizes were calculated using endurance performance mean ± standard
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deviation data from the placebo and paracetamol trials (i.e., the difference in means di-
vided by the pooled standard deviation), total sample size, and correlation between the
trials. Given that none of the studies reported correlation, we have estimated these values
as suggested in the Cochrane Handbook [27]. Sensitivity analyses were performed by
examining the pooled results after excluding one study at a time. As we detected high
heterogeneity in the main meta-analysis (I2 = 79%), we have performed additional analyses
to explore the reasons for this heterogeneity. In one analysis, we only considered the
data from studies that provided paracetamol 45 to 60 min before exercise. Additionally,
subgroup meta-analyses explored the effects of paracetamol ingestion on performance in
time-to-exhaustion tests vs. time trials. Effect sizes were interpreted as trivial (<0.20), small
(0.20–0.49), medium (0.50–0.79), and large (≥0.80) [28]. All meta-analyses were performed
using the random-effects model. Heterogeneity was explored using the I2 statistic, which
was interpreted as low (<50%), moderate (50–75%), and high heterogeneity (>75%). The
statistical significance threshold was set at p < 0.05. All analyses were performed using the
Comprehensive Meta-Analysis software, version 2 (Biostat Inc., Englewood, NJ, USA).
3. Results
3.1. Search Results
In the primary search, there were 754 results (Figure 1). From this number, we read
17 full-text papers and included nine studies [7,9–16]. In the secondary search, there were
another 546 results. The secondary search resulted in the inclusion of one additional
study [8]. Therefore, a total of ten studies were included in the review [7–16].
3.2. Summary of Studies
The included studies were published between 2010 and 2021. Sample sizes varied
from 7 to 29 participants. The pooled number of participants across the ten included studies
was 141. All of the studies included males as participants that were either recreationally
active or competitive athletes. Four studies used a paracetamol dose of 1500 mg [9,10,14,16],
two studies [7,8] used 500 mg, and one study [12] used 1000 mg. Three studies [11,13,15]
provided paracetamol in relative doses, using 20 mg per kg of body mass or per kg of lean
body mass. Paracetamol was ingested 60 min before exercise in six studies [8–12,15], 45 min
before exercise in two studies [13,14], and 120 min before exercise in two studies [7,16]. The
endurance tests used in the included studies are summarized in Table 1. Four studies used
running- or cycling-to-exhaustion tests, whereas others used running or cycling time trials.
Table 1. Summary of studies exploring the effects of paracetamol ingestion on endurance performance.
Study Participants Paracetamol Dose Timing of Ingestionbefore Exercise Endurance Test Main Findings
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Table 1. Cont.
Study Participants Paracetamol Dose Timing of Ingestionbefore Exercise Endurance Test Main Findings
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↑—significant increase; ↔—no significant difference; VO2max—maximum rate of oxygen consumption; a—studies included a
familiarization session.
3.3. Methodological Quality
The included studies scored from 8 to 9 points on the PEDro checklist. Nine studies
were classified as being of excellent methodological quality, while one study [9] was
classified as being of good methodological quality.
3.4. Meta-Analysis Results
All ten studies were included in the main meta-analysis. There was no significant
difference between the effect of placebo and paracetamol on endurance performance
(Cohen’s d = 0.09; 95% confidence interval (CI: −0.04, 0.22; p = 0.172; I2 = 79%; Figure 2).
In the sensitivity analyses, the exclusion of one study [16] had a meaningful effect on
the pooled results, changing the pooled Cohen’s d to 0.14 (95% CI: 0.07, 0.20; p < 0.001;
I2 = 0%). When we considered only studies that provided paracetamol 45 to 60 min before
exercise, there was a significant ergogenic effect on endurance performance (Cohen’s d:
0.14; 95% CI: 0.07, 0.21; p < 0.001; I2 = 0%). In a subgroup analysis that focused only on
endurance performance in time-to-exhaustion tests, there was a significant ergogenic effect
of paracetamol ingestion (Cohen’s d: 0.19; 95% CI: 0.06, 0.33; p = 0.006; I2 = 0%; Figure 3). In
a subgroup analysis that focused only on endurance performance in time trial tests, there
was no significant difference between placebo and paracetamol (Cohen’s d: 0.05; 95% CI:
−0.12, 0.21; p = 0.561; I2 = 85%; Figure 4).
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4. Discussion
When we pooled the data from all available studies, this meta-analysis did not find
a significant difference between the effects of placebo and paracetamol on endurance
performance. However, it appears that the effects of paracetamol are moderated by the
timing of ingestion and the performance test. Specifically, paracetamol was ergogenic for
endurance performance when ingested from 45 to 60 min before exercise. Furthermore,
we also found that paracetamol enhances performance in cycling or running time-to-
exhaustion tests but not in time trials. Still, it should be mentioned that these effects were
in the range of a trivial to small magnitude.
Studies have indicated that the plasma half-life of paracetamol is around 1.5 to
2.5 h [29,30]. However, two studies [7,16] included in the presented review provided
paracetamol 120 min before exercise. These studies did not record an ergogenic effect
and—due to its half-life—this is not likely to be the optimal timing of paracetamol inges-
tion. Indeed, when we considered data from studies that used 45 to 60 min before exercise
as the timing of ingestion, there was a significant ergogenic effect of paracetamol. Thus,
based on the data presented herein, it appears that the timing of ingestion may modulate
the ergogenic effects of paracetamol ingestion on endurance performance. Specifically, it
appears that the optimal timing of paracetamol ingestion is likely to be around 30 to 60 min
before exercise. However, all of the included studies used only one timing of paracetamol
ingestion, which highlights the need for future studies to directly explore the effects of
paracetamol timing on endurance performance.
In subgroup analyses, it was found that paracetamol ingestion enhances performance
in time-to-exhaustion tests, but such effects were not observed in the analysis focusing on
time trials. As mentioned previously, pain reduction is one of the proposed mechanisms
by which paracetamol ingestion enhances exercise performance [20]. Therefore, for parac-
etamol to be ergogenic, it would need to be consumed before exercise that produces high
levels of acute muscle pain. Theoretically, due to their open-end structure, it might be that
time-to-exhaustion tests produce higher levels of acute pain, which is why paracetamol-
induced pain reduction might be ergogenic. However, future work is needed to explore the
relationship between pain perception and the effects of paracetamol ingestion in different
forms of exercise. Paracetamol ingestion also appears to have effects on the attenuation
of neuromuscular fatigue [19]. As recently reported, paracetamol ingestion may increase
muscle activation, which might also improve exercise performance [19]. However, such
effects were observed in resistance exercise, and it remains unclear if they also contribute
to improvements in endurance performance.
It should be mentioned that the included studies varied in the dose of paracetamol
provided to their participants. Specifically, some studies provided paracetamol in doses
relative to body mass (e.g., 20 mg/kg of body mass), whereas other used absolute doses
from 500 to 1500 mg of paracetamol. The latter dose is likely to be more ergogenic given
that paracetamol systemic bioavailability is dose-dependent [29]. Still, the influence of
paracetamol dosing needs to be explored in future dose–response studies. Besides parac-
etamol, more work is also needed on the effects of other analgesic drugs such as tramadol
on endurance performance [31,32].
The focus of the present review was solely on the ergogenic effects of paracetamol on
endurance performance. We did not cover other aspects of paracetamol consumption, such
as safety and ethical concerns [20]. Paracetamol is considered to be safe when taken within
the recommended doses. However, in some countries, overdosing with paracetamol (doses
of 7 g or higher) is one of the most common causes of liver failure [33]. From an exercise
perspective, consumption of paracetamol before and after exercise has been reported to
attenuate markers of anabolic signaling such as the phosphorylation of ribosomal protein
S6, which, depending on the goal of training, also needs to be considered [34]. Ethical
concerns are also an issue, as some have voiced their opinion that paracetamol should be
included in the World Anti-Doping Agency class of substances subjected to Therapeutic
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Use Exemption [35]. These important aspects are covered in more detail in a narrative
review by Lundberg and Howatson [20].
All included studies used a double-blind study design and were classified as being of
good or excellent methodological quality on the PEDro checklist. However, one limitation
was observed among the included studies. Specifically, only one of the ten included studies
evaluated the effectiveness of the blinding to the placebo and paracetamol trials. In the
study that performed this procedure, Tomazini et al. [15] reported that only 14% of the
participants correctly identified the paracetamol trial, suggesting that successful blinding
occurred. Future studies should consider exploring the effectiveness of the blinding, given
that correct supplement identification may impact the outcome of an exercise test and lead
to bias in the results [36,37]. While most studies included a familiarization session, two
studies [7,13] did not report if a familiarization session was incorporated in the study design.
This is important to mention, given that familiarization may impact test reliability [38].
Therefore, future studies should ensure that the participants are adequately familiarized
with the exercise test. On a final point, it should be considered that virtually all included
studies explored the effects of paracetamol ingestion on endurance performance in males.
Therefore, these results should not necessarily be generalized to females, and future studies
in this population are needed. Future studies may also consider directly exploring whether
sex-specific responses to paracetamol’s effect on endurance performance exist.
5. Conclusions
In the present review, we explored the effects of paracetamol ingestion on endurance
performance. When we pooled the data among the ten included studies, there was no
significant difference between placebo and paracetamol for endurance performance. How-
ever, we found an ergogenic effect when we only considered the studies that provided
paracetamol 45 to 60 min before exercise. Additionally, paracetamol ingestion enhanced
performance in time-to-exhaustion endurance tests, but not in time trials. While paraceta-
mol ingestion may enhance endurance performance, these effects are generally in the range
of a trivial to small magnitude. Nevertheless, as this is a fairly novel topic, future research
is needed, particularly related to different doses of paracetamol, the timing of ingestion,
and various endurance tests.
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